Ocugen Inc (OCGN)

$1.51 +0.08 (5.59%)
Market Cap 452.86M
Revenue (ttm) 4.06M
Net Income (ttm) -54.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,331.28%
Debt to Equity Ratio 8.05
Volume 4,890,100
Avg Vol 4,718,978
Day's Range N/A - N/A
Shares Out 312.32M
Stochastic %K 34%
Beta 3.50
Analysts Strong Sell
Price Target $9.00

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 328 4701
Address:
11 Great Valley Parkway, Malvern, United States
BrunoMonteiro
BrunoMonteiro Feb. 4 at 1:55 PM
$OCGN
0 · Reply
Pit1908
Pit1908 Feb. 4 at 1:16 PM
$OCGN 💎OCU400💎 If approved, OCU400 would be one of the first broad gene therapy treatments for RP, potentially treating a wide range of patients with different gene mutations rather than only rare single mutations.
0 · Reply
VINCENZOCOCCOTTI
VINCENZOCOCCOTTI Feb. 4 at 1:13 PM
$OCGN https://www.reddit.com/r/Ocugen/comments/1qvd8bn/nasdaq_ocgn_focusing_on_the_ocu400_phase_3/?%24deep_link=true&correlation_id=44f80280-9271-40f2-a29b-51d2d5b2b837&post_fullname=t3_1qvd8bn&post_index=0&ref=email_digest&ref_campaign=email_digest&ref_source=email&target_user=juddysize&utm_content=post_body&%243p=e_as&_branch_match_id=1445884760001648678&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22QTU7DMBCFT5Pu0qZ2SlOkCCEQW44wcuxJYkhsd2wTyoKzM6HACsmWnr6nN39jSiHe7naExti0VSFsJ%2BtedzLcFaKWoUVQccPSkx2sUxNkmtpxTRXyvhBP%2FJZl2f7ktZ8ZEP9nnQd0LBjN6FJkuT%2B%2FmaZboVPRqDN4PTjovc7RugG8gzQiw1xXFYRRRQS5tpDc5SBqgxhgna6Qj4kyFuJGeyKcVLKctYZ5XfdNJZqqPInjvqyrXpRKnLrysDfCHDrRNfLIueBjgj5Pk1MzruUk%2FA13Na0z%2BM5OxYCwZ4WzshMYO2BMVwhazUHZwf3vRp9J46%2FHMCkaMEGOSExfsjGXaD%2FWPXKaQXuX%2BFDsfA%2FQeXPZfHIdJFqv05FfONg%2BjORn%2FAKOe47cuAEAAA%3D%3D
0 · Reply
Djtrush
Djtrush Feb. 4 at 1:06 PM
$OCGN
0 · Reply
bkhlr
bkhlr Feb. 4 at 12:31 PM
$OCGN
0 · Reply
SiejeUGA
SiejeUGA Feb. 4 at 12:27 PM
$OCGN
0 · Reply
AnchorMB
AnchorMB Feb. 4 at 11:45 AM
$OCGN 2026-2027
0 · Reply
Tipou
Tipou Feb. 4 at 11:41 AM
$OCGN Good morning Bullish
0 · Reply
LittleDerwin
LittleDerwin Feb. 4 at 11:19 AM
$OCGN
0 · Reply
TickerM
TickerM Feb. 4 at 10:49 AM
$OCGN 2026. 🎉💎
0 · Reply
Latest News on OCGN
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 23, 2026, 8:00 AM EST - 12 days ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Jan 21, 2026, 4:37 PM EST - 13 days ago

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 21, 2026, 8:32 AM EST - 14 days ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

Jan 15, 2026, 2:16 PM EST - 19 days ago

Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Jan 15, 2026, 1:15 PM EST - 19 days ago

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 15, 2026, 8:15 AM EST - 20 days ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 13, 2026, 7:00 AM EST - 22 days ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 12, 2026, 6:30 AM EST - 23 days ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Jan 9, 2026, 7:02 AM EST - 26 days ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments

Jan 6, 2026, 12:20 AM EST - 4 weeks ago

Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 10, 2025, 9:20 AM EST - 7 weeks ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 20, 2025, 7:02 AM EST - 2 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:21 PM EST - 3 months ago

Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Nov 5, 2025, 6:30 AM EST - 3 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 3 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Ocugen: A Retinal Disease Juggernaut In The Making

Sep 23, 2025, 11:11 AM EDT - 4 months ago

Ocugen: A Retinal Disease Juggernaut In The Making

Ocugen Shares Are Trading Higher Monday: What's Going On?

Sep 15, 2025, 4:29 PM EDT - 5 months ago

Ocugen Shares Are Trading Higher Monday: What's Going On?

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 15, 2025, 6:03 AM EDT - 5 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Sep 2, 2025, 7:02 AM EDT - 5 months ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 13, 2025, 6:27 AM EDT - 6 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 12, 2025, 3:45 PM EDT - 6 months ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 6 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 12:30 PM EDT - 6 months ago

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Aug 1, 2025, 8:25 AM EDT - 6 months ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 21, 2025, 7:30 AM EDT - 7 months ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 18, 2025, 7:02 AM EDT - 7 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jul 17, 2025, 6:30 AM EDT - 7 months ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 23, 2025, 7:30 AM EDT - 8 months ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Ocugen: Three Potential Gene-Therapy Filings By 2028

Jun 18, 2025, 4:00 PM EDT - 8 months ago

Ocugen: Three Potential Gene-Therapy Filings By 2028

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 16, 2025, 7:02 AM EDT - 8 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

Jun 11, 2025, 7:30 AM EDT - 8 months ago

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Jun 5, 2025, 7:02 AM EDT - 8 months ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025, 7:02 AM EDT - 9 months ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 10:02 AM EDT - 9 months ago

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025, 8:01 AM EDT - 9 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 9 months ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 29, 2025, 7:30 AM EDT - 10 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Apr 8, 2025, 8:02 AM EDT - 10 months ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 11 months ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 10:59 AM EST - 11 months ago

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 27, 2025, 8:46 AM EST - 1 year ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 8:00 AM EST - 1 year ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 12, 2025, 7:42 AM EST - 1 year ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Feb 3, 2025, 6:30 AM EST - 1 year ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 27, 2025, 6:30 AM EST - 1 year ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Jan 16, 2025, 7:30 AM EST - 1 year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Jan 13, 2025, 6:30 AM EST - 1 year ago

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Dec 19, 2024, 6:38 AM EST - 1 year ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Nov 27, 2024, 7:09 AM EST - 1 year ago

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

BrunoMonteiro
BrunoMonteiro Feb. 4 at 1:55 PM
$OCGN
0 · Reply
Pit1908
Pit1908 Feb. 4 at 1:16 PM
$OCGN 💎OCU400💎 If approved, OCU400 would be one of the first broad gene therapy treatments for RP, potentially treating a wide range of patients with different gene mutations rather than only rare single mutations.
0 · Reply
VINCENZOCOCCOTTI
VINCENZOCOCCOTTI Feb. 4 at 1:13 PM
$OCGN https://www.reddit.com/r/Ocugen/comments/1qvd8bn/nasdaq_ocgn_focusing_on_the_ocu400_phase_3/?%24deep_link=true&correlation_id=44f80280-9271-40f2-a29b-51d2d5b2b837&post_fullname=t3_1qvd8bn&post_index=0&ref=email_digest&ref_campaign=email_digest&ref_source=email&target_user=juddysize&utm_content=post_body&%243p=e_as&_branch_match_id=1445884760001648678&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22QTU7DMBCFT5Pu0qZ2SlOkCCEQW44wcuxJYkhsd2wTyoKzM6HACsmWnr6nN39jSiHe7naExti0VSFsJ%2BtedzLcFaKWoUVQccPSkx2sUxNkmtpxTRXyvhBP%2FJZl2f7ktZ8ZEP9nnQd0LBjN6FJkuT%2B%2FmaZboVPRqDN4PTjovc7RugG8gzQiw1xXFYRRRQS5tpDc5SBqgxhgna6Qj4kyFuJGeyKcVLKctYZ5XfdNJZqqPInjvqyrXpRKnLrysDfCHDrRNfLIueBjgj5Pk1MzruUk%2FA13Na0z%2BM5OxYCwZ4WzshMYO2BMVwhazUHZwf3vRp9J46%2FHMCkaMEGOSExfsjGXaD%2FWPXKaQXuX%2BFDsfA%2FQeXPZfHIdJFqv05FfONg%2BjORn%2FAKOe47cuAEAAA%3D%3D
0 · Reply
Djtrush
Djtrush Feb. 4 at 1:06 PM
$OCGN
0 · Reply
bkhlr
bkhlr Feb. 4 at 12:31 PM
$OCGN
0 · Reply
SiejeUGA
SiejeUGA Feb. 4 at 12:27 PM
$OCGN
0 · Reply
AnchorMB
AnchorMB Feb. 4 at 11:45 AM
$OCGN 2026-2027
0 · Reply
Tipou
Tipou Feb. 4 at 11:41 AM
$OCGN Good morning Bullish
0 · Reply
LittleDerwin
LittleDerwin Feb. 4 at 11:19 AM
$OCGN
0 · Reply
TickerM
TickerM Feb. 4 at 10:49 AM
$OCGN 2026. 🎉💎
0 · Reply
Jessmaster
Jessmaster Feb. 4 at 10:41 AM
$OCGN
0 · Reply
Joe_088
Joe_088 Feb. 4 at 9:55 AM
$OCGN
0 · Reply
icervantes
icervantes Feb. 4 at 9:27 AM
$OCGN
0 · Reply
CaptScotty
CaptScotty Feb. 4 at 9:24 AM
$OCGN
0 · Reply
giglio75
giglio75 Feb. 4 at 9:18 AM
$OCGN 👁👀
0 · Reply
Skindlo
Skindlo Feb. 4 at 7:45 AM
$OCGN whay is this happening?🥲 @TheUrbanFarmer
1 · Reply
nick2341
nick2341 Feb. 4 at 7:25 AM
$OCGN good morning from cold Amsterdam
2 · Reply
SIRWINSALOT
SIRWINSALOT Feb. 4 at 4:29 AM
$OCGN yes he’s very smart! Securing funding to complete phase 3 and BLA submission is about as smart as you can get! And each time he secure his funding he does it at a higher price. This is great for our Stock movement! 
0 · Reply
Tomassso
Tomassso Feb. 4 at 4:18 AM
$OCGN remember, if this gets to 2.5 dollars, Shankar already signed docs to issue more shares, further delute them. Shankar is a smart guy.
0 · Reply
thegreenhammer
thegreenhammer Feb. 4 at 1:24 AM
$OCGN can you see it ! 👇🏽⏰💣💥👋🏽😎
1 · Reply
thegreenhammer
thegreenhammer Feb. 4 at 1:22 AM
$OCGN https://x.com/rmagiccorner/status/2018854113241702669?s=46
1 · Reply
ichigoDuzumaki
ichigoDuzumaki Feb. 4 at 1:11 AM
$OCGN 1 year chart MOFO’s. Zoom out every now & then. To the bitch ass bears,
0 · Reply